Medicine and Dentistry
Tyrosine-Kinase Inhibitor
50%
In Vitro
50%
Endothelial Cell
50%
Cell Function
50%
Cell Survival
50%
Dasatinib
29%
Ponatinib
26%
Vincristine
25%
Dacarbazine
25%
Vinblastine
25%
Pooled Analysis
25%
Bleomycin
25%
Prednisone
25%
Procarbazine
25%
Vincristine Sulfate
25%
Nilotinib
21%
Cell Adhesion Molecule
18%
Assay
14%
Therapeutic Procedure
13%
Cell Migration
13%
Endothelial Leukocyte Adhesion Molecule 1
11%
Vascular Cell Adhesion Molecule 1
11%
Intercellular Adhesion Molecule 1
11%
Cells
11%
Chronic Myelogenous Leukemia
9%
Bosutinib
9%
Drug Megadose
9%
Lactate Dehydrogenase
9%
Atherosclerosis
8%
Enzyme Linked Immunosorbent Assay
8%
Imatinib
6%
Necrosis
6%
Atherogenesis
6%
Programmed Cell Death
5%
Pharmacology, Toxicology and Pharmaceutical Science
Protein Tyrosine Kinase Inhibitor
100%
Chronic Myeloid Leukemia
60%
Survival
50%
Ponatinib
49%
Nilotinib
49%
Dasatinib
49%
Rupture
25%
Long Term Survival
25%
Overall Survival
25%
Imatinib
20%
Cell Adhesion Molecule
18%
Bosutinib
17%
Intercellular Adhesion Molecule 1
12%
Vascular Cell Adhesion Molecule 1
12%
E-Selectin
12%
Gelatinase B
11%
Gelatinase A
11%
Lactate Dehydrogenase
10%
Atherosclerosis
8%
Enzyme-Linked Immunosorbent Assay
8%
Necrosis
6%
Atherogenesis
6%
Gelatin
6%
Lipoprotein
5%
Wound
5%
Blood Vessel Occlusion
5%
Cardiovascular Risk
5%
Artery Occlusion
5%
Metabolic Syndrome X
5%
Randomized Clinical Trial
5%
Comorbidity
5%
Myeloid Leukemia
5%
Matrix Metalloproteinase
5%
Biochemistry, Genetics and Molecular Biology
Tyrosine Kinase Inhibitor
50%
Myeloid
31%
Ponatinib
28%
Cell Function
25%
Taxonomy
25%
Nilotinib
25%
Overall Survival
25%
Cell Survival
25%
Association
25%
Dasatinib
23%
Imatinib
11%
Bosutinib
10%
Adhesion
9%
Molecule
9%
ICAM-1
6%
VCAM-1
6%
Cell Migration
6%
Wound Healing Assay
6%
Drug Megadose
6%
E-Selectin
6%